Retinal Sensitivity in BRVO After Anti-VEGF Therapy

Sponsor
Fukushima Medical University
Study ID
NCT02527733
Phase
PHASE4
Status
Unknown

Conditions

  • Branch Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.

Key Dates

First listed
Aug 19, 2015
Start date
Jun 30, 2015
Status verified
Aug 2015
Primary completion
Sep 30, 2017

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Ranibizumab
    After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
  • Active Comparator: Ranibizumab and laser
    After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.

Primary Outcome Measure

Retinal sensitivity measured by microperimetry (MP-3, NIDEK, Japan) [ Time Frame: At 12 months ]

Central Contacts